Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated by Analysts at Robert W. Baird

Robert W. Baird assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE) in a research report sent to investors on Thursday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $50.00 price target on the stock.

SYRE has been the subject of several other research reports. Stifel Nicolaus increased their price target on Spyre Therapeutics from $36.00 to $54.00 and gave the stock a buy rating in a research note on Tuesday, March 26th. Wells Fargo & Company upgraded shares of Spyre Therapeutics from an equal weight rating to an overweight rating and raised their price objective for the company from $12.00 to $35.00 in a research note on Friday, March 1st. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of Buy and an average price target of $41.00.

Spyre Therapeutics Price Performance

NASDAQ:SYRE traded down $0.49 during mid-day trading on Thursday, hitting $35.78. The stock had a trading volume of 196,820 shares, compared to its average volume of 323,984. The stock’s 50 day moving average is $36.20. The stock has a market capitalization of $1.29 billion, a PE ratio of -0.48 and a beta of 2.93. Spyre Therapeutics has a 52 week low of $2.66 and a 52 week high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.80). Equities research analysts anticipate that Spyre Therapeutics will post -2.36 EPS for the current year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).